Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

Sales of Cobenfy, a new mind-stabilizing medicine ... on an earnings call that the “launch is really off to a strong start” and the company has “made very good progress achieving our ...

BMS reported sales of $10 million for Cobenfy in the fourth quarter as the launch is off to a “great start,” according to Boerner, who added that the company has initiated seven phase 3 ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment. The ...

We also achieved the landmark U.S. approval of Cobenfy last year for the treatment of schizophrenia in adults, and we expect this medicine to have a meaningful impact on patients and the company ...

InvestingPro subscribers have access to over 30 additional financial metrics and exclusive analysis. The approval of Cobenfy, a new treatment for schizophrenia, has emerged as a potential growth ...